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The Cost-Effectiveness of Vancomycin
Powder in Lumbar Laminectomy
Yehuda E. Kerbel, MD1, Gregory J. Kirchner, MPH1 ,
Anisha Reddy Sunkerneni, BS1, Alexander M. Lieber, BA1 ,
Vincent M. Moretti, MD2,3, Amrit S. Khalsa, MD1,
and Marc J. Levine, MD4
Abstract
Study Design: Break-even cost analysis.
Objective: The goal of this study is to examine the cost-effectiveness of vancomycin powder for preventing infection following
lumbar laminectomy.
Methods: The product cost of vancomycin powder was obtained from our institution’s purchasing records. Infection rates and
revision costs for lumbar laminectomy and lumbar laminectomy with fusion were obtained from the literature. A break-even
analysis was then performed to determine the absolute risk reduction (ARR) in infection rate to make prophylactic application of
vancomycin powder cost-effective. Analysis of lumbar laminectomy with fusion was performed for comparison.
Results: Costing $3.06 per gram at our institution, vancomycin powder was determined to be cost-effective in lumbar lami-
nectomy if the infection rate of 4.2% decreased by an ARR of 0.015%. Laminectomy with fusion was also determined to be cost-
effective at the same cost of vancomycin powder if the infection rate of 8.5% decreased by an ARR of 0.0034%. The current
highest cost reported in the literature, $44.00 per gram of vancomycin powder, remained cost-effective with ARRs of 0.21% and
0.048% for laminectomy and laminectomy with fusion, respectively. Varying the baseline infection rate did not influence the ARR
for either procedure when the analysis was performed using the product cost of vancomycin at our institution.
Conclusions: This break-even analysis demonstrates that prophylactic vancomycin powder can be highly cost-effective for
lumbar laminectomy. At our institution, vancomycin powder is economically justified if it prevents at least one infection out of
6700 lumbar laminectomy surgeries.
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cost-benefit analysis, economic models, laminectomy, lumbar, vancomycin
Introduction
Infection following lumbar laminectomy with fusion is both
devastating and costly.1 The average cost of revision following
an infected lumbar laminectomy with fusion has recently been
reported as $90 938.2 The rates of infection with different
organisms following spine surgery vary by study; however,
some of the most frequent organisms identified are gram-
positive cocci including methicillin-resistant Staphylococcus
aureus (MRSA) and Staphylococcus epidermidis.3 Increasing
methicillin resistance has decreased the efficacy of intravenous
cephalosporins as the standard preoperative antibiotic prophy-
laxis used in orthopedic procedures in general, and spine
surgery in particular.3-5
Studies have reported that more than 60% of wound infec-
tion isolates in the United States are cephalosporin-resistant,
including MRSA and coagulase-negative Staphylococcus.6,7
Among orthopedic patients in the United States, 20% to 30%
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have anterior nares colonized by methicillin-sensitive S aureus
(MSSA), and 2% to 6% are colonized by MRSA.8 Patients
colonized preoperatively with MSSA face an added risk of
surgical site infection 9 to 10 times greater than those who are
not colonized, whereas patients preoperatively colonized with
MRSA face an added risk of up to 4 times greater than those
colonized with MSSA.8 The incidence of MRSA colonization
among orthopedic patients is particularly concerning due to
the virulent nature of the microbe. It not only poses a greater
risk but is also more difficult to treat and, as a result, more
expensive to the health care system.9 Rising prevalence of
methicillin resistance and recognition of S aureus coloniza-
tion as a modifiable risk factor for wound infection has
resulted in a growing adoption of prophylactic antibiotic
usage in spine surgery to prevent infection with S aureus and
other gram-positive microbes.10,11
In particular, vancomycin powder has been added as a local
application in wound beds for cardiac, vascular, spine, and a
variety of other orthopedic procedures.10,11 The effect has been
a demonstrable decrease in infection without any appreciable
complications.12,13 Sweet et al found that the addition of van-
comycin powder to traditional intravenous antibiotics reduced
the deep infection rate after thoracic and lumbar instrumented
spinal fusions from 2.6% to 0.2%, with no adverse clinical or
wound complications.13 Other studies have found a decrease in
infection from 15% to 0% with the addition of vancomycin
powder in instrumented posterior cervical spine fusions and a
decrease from 13% to 0% when vancomycin was added to
posterior spinal fusions for trauma.14,15
The cost-effectiveness of vancomycin powder as a means of
infection prophylaxis in lumbar laminectomy with fusion has
been assessed in prior studies. In a retrospective review of 110
patients with traumatic spine injuries treated with instrumented
posterior spine fusions over a 2-year period at a single institu-
tion, Godil et al16 found that vancomycin powder led to cost-
savings of $438 165 per 100 spinal fusions performed, while
Emohare et al17 found that their use of vancomycin powder in
posterior instrumented spine surgery saved their hospital more
than $500 000 over a 2-year span.
However, to our knowledge, no prior studies have examined
the cost-effectiveness of vancomycin powder when utilized spe-
cifically for simple laminectomy without concomitant fusion.
The goal of this study was to examine the cost-effectiveness of
vancomycin powder in lumbar laminectomy without fusion using
a simple break-even cost analysis that any spine surgeon can
utilize to determine the exact economic viability of intraoperative
vancomycin powder for their specific practice. This study also
compared the cost-effectiveness of vancomycin powder for lum-
bar laminectomy in comparison to lumbar laminectomy with
fusion to determine the degree to which the added fusion proce-
dure changes the overall break-even economic calculations.
Materials and Methods
As an economic model for determining cost-effectiveness,
we utilized a break-even analysis originally described by
Hatch et al (Figure 1).18 This equation produces the final
break-even infection rate necessary to make a protocol cost-
effective, given the initial infection rate, the total cost of
treating an infection, and the cost of a treatment or prevention
protocol. These values were determined from the literature and
our institution’s purchasing records. Calculating the difference
between the initial and final infection rates yields the absolute
risk reduction (ARR), which is the percent by which a proto-
col must reduce the infection rate to economically justify its
use as a prophylactic measure. Clinicians can tailor this equa-
tion to their practice, by using their preferred method and
institutional product costs, to determine the ARR of their
given protocol.
Prior studies have shown drastically different rates of
both infection and cost of revision when comparing lumbar
laminectomy with fusion to simple laminectomy alone.
Reported literature values for baseline infection rates after
lumbar laminectomy with fusion are 8.50%, while infection
rates from lumbar laminectomy alone are 4.20%.2,19 The
average total hospital cost of revision following infection
after lumbar laminectomy with fusion has been reported
as $90 938, while the total hospital cost of revision for
infected lumbar laminectomy alone is much lower at
$21 060.20,21 The product cost of vancomycin powder was
obtained from our institution’s purchasing records and was
found to be $3.06 per gram. Within the literature, the cost of
vancomycin powder was found to range from $2.50 to
$44.13,16-18,22,23
Results
Costing $3.06 per gram at our institution, vancomycin powder
was determined to be cost-effective in lumbar laminectomy if
the infection rate of 4.2% decreased by an ARR of 0.015%
(Table 1). Laminectomy with fusion was determined to be
cost-effective at the same cost of vancomycin powder if the
infection rate of 8.5% decreased by an ARR of 0.0034%.
The current highest cost of vancomycin reported in the lit-
erature, $44.00 per gram, was cost-effective with ARRs of
0.21% and 0.048% for laminectomy alone and laminectomy
with fusion, respectively.
Additional calculations were performed using a wide range
of infection rates, taking into consideration the fact that infec-
tion rates after lumbar procedures vary in the literature and are
also presumed to vary by institution and surgeon. For these
Stotal  Ct  IRi ¼ ðStotal  CdÞ þ ðStotal  Ct  IRf Þ
Solving for IRf yields:
IRf ¼ ðIRiCtÞCd
Ct
Figure 1. Equation used to calculate the break-even infection rate.
Where: Stotal ¼ total annual surgeries; Ct ¼ total cost of treating an
infection; Cd¼ cost of drug; IRi¼ initial infection rate; IRf ¼ breakeven
infection rate. Adapted from Hatch et al.18
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analyses, the costs of revision following infection after both
procedures were held constant. These calculations demon-
strated that even at initial infection rates as high as 10%, the
cost-effectiveness of vancomycin powder in both procedures
remained unchanged with an ARR of 0.015% for lumbar
laminectomy alone and 0.0034% for laminectomy with
fusion (Table 2).
To determine how much impact the cost of revision had on
the break-even analysis, the ARR was calculated when the
initial rate of infection and the cost of vancomycin powder was
held constant across various costs of revision. The results
showed that the ARR does vary based on the revision rate, but
most of the variation is at extremes of cost and is not clinically
relevant (Table 3).
Discussion
The intra-wound application of vancomycin powder has been
utilized for infection prophylaxis across a variety of surgical
specialties, including multiple subspecialties of orthopedic sur-
gery.10,11 The effect has been a demonstrable decrease in infec-
tion without any appreciable complications.12,13 With regard to
spine surgery, Sweet et al demonstrated that vancomycin pow-
der reduced the deep infection rate after thoracic and lumbar
instrumented spinal fusions from 2.6% to 0.2% compared to
traditional intravenous antibiotics, with no adverse clinical or
wound complications.13 Additional studies have reported pre-
cipitous decreases in infection rates with vancomycin powder
prophylaxis in spine surgeries, such as instrumented posterior
cervical spine fusions (15% to 0%), posterior spinal fusions for
trauma (13% to 0%), and complex posterior instrumented spine
surgery (10% to 5%).14,15,24
Given the recent economic changes in orthopedic reimbur-
sement, including the trend toward bundle payments, minimiz-
ing costs while improving efficacy and patient outcomes is
more important than ever before.25-27 There is a dearth of pub-
lished data on the economic burden of infection after lumbar
laminectomy with fusion, but the limited studies that have
described these costs have uniformly shown the tremendous
economic burden of an infected spinal surgery, particularly
with implants.1 A recent study by Patel et al identified post-
operative spinal infection as one of the most expensive causes
of readmission and concluded that patients with spine surgery
incur approximately double the health care costs when they
develop a surgical site infection.28
The most common organism causing infection after lumbar
laminectomy with fusion is S aureus, estimated to account for
Table 2. Maintaining Cost of Vancomycina and the Cost of Treating
Infection Constant Does Not Change Cost-Effectiveness.
Initial Infection
Rateb (%)
Laminectomy Laminectomy and Fusion
Final Infection
Rate (%) ARR (%)
Final Infection
Rate (%) ARR (%)
0.50 0.49 0.0145 0.50 0.0034
1 0.99 0.0145 1.00 0.0034
2 1.99 0.0145 2.00 0.0034
3 2.99 0.0145 3.00 0.0034
4 3.99 0.0145 4.00 0.0034
5 4.99 0.0145 5.00 0.0034
6 5.99 0.0145 6.00 0.0034
7 6.99 0.0145 7.00 0.0034
8 7.99 0.0145 8.00 0.0034
9 8.99 0.0145 9.00 0.0034
10 9.99 0.0145 1.00 0.0034
Abbreviation: ARR, absolute risk reduction.
aCost of vancomycin $3.06 per gram at our institution.
bPresumes cost of treating infection is $21 060 for laminectomy and $90 938
for laminectomy and fusion.
Table 3. Maintaining Cost of Vancomycina and Initial Rate of
Infectionb Constant Changes Cost-Effectiveness.
Cost of Treating
Infection (US$)
Laminectomy Laminectomy and Fusion
Final Infection
Rate (%) ARR (%)
Final Infection
Rate (%) ARR (%)
500 3.59 0.6120 7.89 0.6120
1000 3.89 0.3060 8.19 0.3060
5000 4.14 0.0612 8.44 0.0612
10 000 4.17 0.0306 8.47 0.0306
21 060c 4.19 0.0145 8.49 0.0145
30 000 4.19 0.0102 8.49 0.0102
40 000 4.19 0.0077 8.49 0.0076
50 000 4.19 0.0061 8.49 0.0061
75 000 4.20 0.0041 8.50 0.0041
90 938d 4.20 0.0034 8.50 0.0034
100 000 4.20 0.0031 8.50 0.0031
120 000 4.20 0.0025 8.50 0.0025
Abbreviation: ARR, absolute risk reduction.
aCost of vancomycin $3.06 per gram at our institution.
bPresumes initial rate of infection is 4.20% for laminectomy and 8.50% for
laminectomy and fusion.
cDenotes literature value of treating infected laminectomy.
dDenotes literature value of treating infected laminectomy and fusion.
















2.50 4.19 0.01 8.50 0.003
3.06a 4.19 0.01 8.50 0.003
10.00 4.15 0.05 8.49 0.01
17.00 4.12 0.08 8.48 0.02
34.00 4.04 0.16 8.46 0.04
44.00 3.99 0.21 8.45 0.05
50.00 3.96 0.24 8.45 0.05
75.00 3.84 0.36 8.42 0.08
100.00 3.73 0.47 8.39 0.11
Abbreviation: ARR, absolute risk reduction.
aValue at our institution.
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up to 90% of all infection following these operations.28 The
incidence of MRSA in spinal surgery has been found to
account for an estimated 25% to 52% of all S aureus isolates
from infected spine procedures.28 Infection with this micro-
organism is particularly worrisome, as prior studies have
shown that treatment outcomes are less successful and more
costly for patients.9,29 Thus, there has been an increased focus
on preventing MRSA infections after lumbar laminectomy
with fusion by utilizing local vancomycin powder
intraoperatively.12,22,30
In addition to its advantageous antimicrobial properties,
vancomycin powder has also gained popularity due to its
cost-effectiveness.16,17 However, prior cost-effectiveness stud-
ies have looked at cost-effectiveness either from a macroeco-
nomic standpoint or utilizing institution-specific values that
may not apply to other practices.16,17 In addition, prior studies
have looked at the cost-effectiveness of vancomycin powder
for laminectomy with instrumented fusion but have failed to
examine the cost-effectiveness in laminectomy alone or to pro-
vide a cost-effectiveness comparison between the 2 procedures.
Despite the growing body of evidence supporting the effi-
cacy of vancomycin powder for infection prophylaxis in ortho-
pedic surgery, many researchers remain concerned regarding
the routine prophylactic use of a potent antimicrobial agent. In
a recent investigation of patients who underwent irrigation and
debridement of wound infections following elective thoracic or
lumbar surgery, Grabel et al found that polymicrobial infec-
tions and infection with gram-negative organisms was signifi-
cantly more common among patients who had received
vancomycin powder prophylaxis during the index procedure.31
Nevertheless, Grabel et al did not appreciate any differences
between infected spine patients who received vancomycin
powder and those who did not regarding rate of requiring
greater than one antibiotic to treat the infection. However, the
rate of repeated irrigation and debridement was significantly
less in the vancomycin-treated group.31
There are a few important considerations derived from this
break-even equation. First, the major determinant of cost-
effectiveness is the cost of the vancomycin powder itself. At
our institution, the cost of the powder was low at $3.06; how-
ever, even at inflated values as high as $44.00, it remained cost-
effective for both procedures. Second, the baseline infection
rate does not affect the ARR obtained at any specific cost of
vancomycin powder. When both the cost of treating an infec-
tion and the cost of the powder were kept constant, the final
break-even ARR remained unchanged for both procedures,
regardless of initial infection rate. Finally, the cost of treating
an infection does make a difference, but the difference is prob-
ably subclinical at the current cost levels estimated in the lit-
erature. When the cost of vancomycin powder and the initial
infection rates were kept constant, the ARR for vancomycin
powder varied very little when calculated within the cost
ranges of treating an infection cited in the literature.
The utility of this break-even equation is that it provides a
straightforward method to determine the economic viability of
vancomycin powder for lumbar laminectomy with and without
fusion, even though the incidence of infection is low enough to
preclude a randomized controlled trial. For instance, assuming
that vancomycin powder has a hypothetical ARR of 0.02%, the
number needed to treat to prevent an infection would be 1 in
5000. To determine this same result in a clinical trial using a
power analysis, the sample size, assuming P < .05 and power¼
80%, would need to be extremely high (15 366 400). In our
case, even with the most expensive vancomycin powder cost,
which requires the largest ARR of 0.21% for laminectomy
without fusion, the sample size remains prohibitively large at
139 378. Likewise, laminectomy with fusion, which requires an
ARR of 0.048% at the most expensive cost of vancomycin,
would require an even larger sample size of 2 667 778, which
is an impossible number of patients to follow in a clinical study.
Thus, this equation serves as an extremely useful tool for any
clinician to determine the cost-effectiveness of intraoperative
vancomycin powder utilization, both in simple lumbar lami-
nectomy and in any other spine procedure. All the clinician
requires is their initial infection rate, the costs of surgical revi-
sion for a given procedure at their institution, and their pur-
chasing costs for vancomycin powder, and they can calculate
the cost-effectiveness of vancomycin powder for any procedure
used in their own practice.
Based on our results, we believe that vancomycin powder
is a cost-effective measure for the prevention of infection in
both lumbar laminectomy with fusion and lumbar laminect-
omy alone, although it is more cost-effective when used for
laminectomy with fusion. Despite the fact that the efficacy of
vancomycin powder has not been directly examined in simple
lumbar laminectomy, its efficacy has been documented in
noninstrumented lumbar procedures.22 The choice to utilize
this modality intraoperatively should be a multifactorial deci-
sion that includes individualized patient and physician deci-
sion making, as well as institutional infection rates and
protocols. It is important to note that we are not recommend-
ing that all institutions utilize vancomycin powder in all their
laminectomy procedures. This article simply aims to serve as
an objective cost-analysis model for physicians to use when
considering the financial aspects of their spine surgery infec-
tion prevention algorithm.
While this study provides a useful framework for any clin-
ician to improve the cost-effectiveness of their practice, it con-
tains several flaws. First, the cost and infection data are not
exact and are liable to fluctuate between different institutions.
Our infection data was based on national estimates provided in
the literature, which may vary greatly by practice and patient
population. Second, this study only considers a single type of
spine surgery and may not be generalizable to other spinal
procedures or differing techniques, such as minimally invasive
versus open. Third, modelling can only account for averages
and does not include individualized patient and regional demo-
graphics. We believe, however, that this model still provides a
useful conceptual framework for overall practice management
that can be deviated from for anomalous or complex patients.
Finally, our study does not consider the noneconomic aspects
of these protocols, such as antibiotic resistance and the wider
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public health implications of using vancomycin powder in all
patients. We deliberately chose to focus this article solely on
the economic implications of this treatment protocol.
This break-even analysis demonstrates that prophylactic
intra-wound application of vancomycin powder can be highly
cost-effective not only for lumbar laminectomy with fusion but
also for laminectomy alone. At our institution’s price point, the
use of vancomycin powder is economically justified if it pre-
vents at least one infection out of 6667 lumbar laminectomy
surgeries. By comparison, the use of vancomycin powder in
lumbar laminectomy with fusion would be cost-effective if it
prevented at least one infection out of 29 411 surgeries. Addi-
tionally, the baseline infection rate did not affect the ARR of
the protocols studied, with the ARR of vancomycin powder
remaining constant at both extremely low and high initial infec-
tion rates. Finally, the cost of treating an infection did affect the
ARR of the protocols studied when extreme values were used
but had no clinical significance at the average cost ranges cited
in the literature. This break-even analysis is easily adaptable to
the individual practices of academic institutions or private
practice surgeons, providing a useful economic analysis tool
for the practicing spine surgeon.
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